key: cord-1024305-1x4pjq3x
authors: Nair, Abhijit
title: Non-steroidal anti-inflammatory drugs in COVID-19 patients- What is the verdict?
date: 2021-09-02
journal: Saudi J Anaesth
DOI: 10.4103/sja.sja_313_21
sha: d4325b8d12e943261d16b701d6de480b7d993d65
doc_id: 1024305
cord_uid: 1x4pjq3x

nan

In patients who have a positive reverse transcriptase-polymerase chain reaction (RT-PCR) test from a nasopharyngeal swab indicating COVID-19 infection because of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the severity of the cytokine storm decides the overall outcome of the illness. When the pandemic of COVID-19 was announced and researchers were still fathoming the complex pathophysiology because of SARS-CoV-2, it was announced that non-steroidal anti-inflammatory drugs (NSAIDs) should not be used in these patients for managing pyrexia, inflammation, and other constitutional symptoms like myalgia and headache. [1] The popular NSAID ibuprofen has been implicated to increase the levels of angiotensin-converting enzyme-2 (ACE2), its expression within the renin-angiotensin-aldosterone system which is the coreceptor for the entry of SARS-CoV-2 into lung parenchymal cells. Therefore, it is hypothesized that the use of NSAIDs could lead to an increased risk of contracting COVID-19 disease or worsening of COVID-19 infection if consumed once the disease is confirmed. [2] This hypothesis is still under evaluation.

In a retrospective cohort study of 403 COVID-19 patients from a single-centre, Rinott et al. [3] analyzed the need for respiratory support including assisted ventilation and mortality in patients who received either ibuprofen or paracetamol as an antipyretic during treatment. On analysis, the authors concluded that the use of ibuprofen was not associated with worse clinical outcomes when compared to paracetamol. In a prospective cohort study involving 503 COVID-19 patients which involved patients who received acute NSAID therapy, patients on chronic NSAID/aspirin, and non-NSAID users; Abu Esba et al. [4] concluded that acute or chronic use of any NSAIDs was associated with adverse outcomes. The limitations of this study were its observational nature, many confounding factors, presence of selection bias, and that it was a single institute experience.

The mechanism of action of NSAIDs is by inhibiting cyclooxygenase I and II (COX-I and COX-II), which mediates prostaglandins leads to its anti-inflammatory properties. It has been demonstrated that prostaglandin inhibition modifies the expression of angiotensin-converting enzyme 2 (ACE2), regulates replication of SARS-CoV-2 in host cells, and modulating the immune response to SARS-CoV-2. This was demonstrated in a study by Chen et al. involving human cell cultures and mouse systems. [5] The authors demonstrated that COX inhibition did not affect ACE2 expression, viral entry, or viral replication. On the contrary, there was a dampening of the inflammatory response owing to its anti-inflammatory effects and production of protective antibodies. The limitation of this study is that the data is from human cell cultures and animal studies. Animal studies have demonstrated a decrease in IL6 and TNF-α when COX2 inhibitor celecoxib is used. These properties have not been effectively explored in the current pandemic.

The cytokine storm in severe COVID-19 infection leads to the release of proinflammatory cytokines in the circulation which leads to acute respiratory failure, shock, multiorgan dysfunction, and shock. The cytokine storm is also responsible for lymphopenia which has shown to be directly related to mortality (lymphocyte count of less than 1.5 × 10 9 /L, is associated with a 3-fold increased risk of severe COVID-19 infection). There was a significant reduction in T-cells and natural killer cells as well. Neutrophil-lymphocyte-ratio is found to have a good predictive value on the severity of COVID-19 illness and mortality. [6] Based on this understanding, it was hypothesized that if NSAIDs are used early in COVID-19 infection for their anti-inflammatory properties, it could help in reducing the intensity of cytokine storm. Anti-inflammatory agents or cytokine antagonists like tocilizumab (IL-6 inhibitor) or anakinra (IL-1 receptor antagonist), Janus kinase inhibitors are being advocated in indicated patients which interferes with cytokine storm at various levels. Several studies are currently prospectively investigating the efficacy and safety of NSAID in COVID-19 illness.

The beneficial effects of NSAIDs, although anecdotal, should be taken with a pinch of salt. NSAIDs causing prostaglandin inhibition leads to PGI2 inhibition and also potentiates thrombosis, which can be harmful in COVID-19 patients. The use of NSAIDs has been responsible for serious thrombotic phenomena like major adverse cardiovascular, cerebrovascular, and lower limb thrombotic events. NSAIDs use can precipitate bronchospasm in susceptible patients which could complicate pre-existing respiratory status. [7] Acute kidney injury in COVID-19 patients is associated with significant morbidity and mortality. The use of NSAIDs could thus be detrimental in patients with borderline renal functions especially in patients who are hypertensive, diabetic, coronary artery disease, and the elderly population. [8] This leaves with clinicians a selective Non-steroidal anti-inflammatory drugs in COVID-19 patients-What is the verdict?

Saudi Journal of Anesthesia / Volume 15 / Issue 4 / October-December 2021 proportion of patients in whom NSAIDs could be used safely, with close monitoring.

To conclude, the safety of NSAIDs as an anti-inflammatory and antipyretic is not established yet. Well-designed, prospective studies might be able to establish the efficacy, timing, dose, and duration of NSAIDs in selected COVID-19 patients. Paracetamol when used in appropriate doses appears to be safer and reasonably effective for managing pyrexia and myalgia.

Financial support and sponsorship Nil.

There are no conflicts of interest.

Covid-19: Ibuprofen should not be used for managing symptoms, say doctors and scientists

COVID-19 and avoiding ibuprofen. How good is the evidence?

Bar-Haim A, Youngster I. Ibuprofen use and clinical outcomes in COVID-19 patients

Ibuprofen and NSAID use in COVID-19 infected patients is not associated with worse outcomes: A prospective cohort study

Non-steroidal anti-inflammatory drugs dampen the cytokine and antibody response to SARS-CoV-2 infection

Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis

NSAIDs may increase the risk of thrombosis and acute renal failure in patients with COVID-19 infection

Outcomes among patients hospitalized with COVID-19 and acute kidney injury

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. Prolotherapy as an intervention for chronic, refractory musculoskeletal painTo the Editor, Proliferative injection therapy or prolotherapy, also called regeneration therapy, is an interventional modality used for various chronic painful musculoskeletal conditions. Prolotherapy involves a small volume of local anesthetic injections with or without a sclerosing or irritant agent into the connective tissues between the ligament or tendon and bone, or intra-articular space. These injections can be repeated based on the requirement. The mechanism of the action of prolotherapy is postulated as by activation of an inflammatory response at the site of the injection, increasing levels of growth factors after injections as a result of which there will be regenerative processes in cells in the vicinity. It is also postulated that there is stimulation of fibroblast and vascular proliferation, deposition of dense collagen, and cartilage growth around the area of injection. This modality has not become very popular because it is used as the last weapon from the armamentarium of pain physicians when all other therapies like medications, various other interventional